Loading stock data…
Apyx Medical Corporation (APYX)
$3.05-0.01 (-0.33%)
Pre-Market$3.11+0.06 (+1.97%)· Last close Sep 4
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apyx Medical Corporation in the Healthcare sector is trading at $3.05 with a market capitalization of $129M. Wall Street consensus targets $6.60 (5 analysts), implying a +116.4% move over the next 12 months. The stock is currently 40% below its 52-week high of $5.08, remaining 19.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +116.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.49M↓ | $19.16M↑ | $12.88M↑ | $11.37M↑ | $9.43M |
| Gross Profit | $7.92M↓ | $12.00M↑ | $8.30M↑ | $7.08M↑ | $5.67M |
| Operating Income | -$911,000↓ | $11,000↑ | -$832,000↑ | -$2.57M↑ | -$3.05M |
| Net Income | -$2.11M↓ | -$1.30M↑ | -$1.98M↑ | -$3.78M↑ | -$4.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$128.90M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.97%
Volume
Today's trading volume
62,059
Recent News
Apyx Medical (APYX) Q2 2026 Earnings Call Transcript
AYON adoption accelerated 22% as surgeons target GLP-1 weight-loss patients.
Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
Apyx Medical (NASDAQ:APYX) is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs. Speaking at the Canaccor
Apyx Medical Corp (APYX) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% on Power Lipo ...
Company capitalizes on expanded FDA clearance and growing body contouring demand, reaffirming full-year guidance despite margin headwinds.
Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates
Apyx (APYX) delivered earnings and revenue surprises of -16.67% and +10.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical Q2 Earnings Call Highlights
Apyx Medical (NASDAQ:APYX) reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces. Total revenue for the quarter ended June